Justine V. Cohen

11.9k total citations · 2 hit papers
96 papers, 3.4k citations indexed

About

Justine V. Cohen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Justine V. Cohen has authored 96 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 27 papers in Molecular Biology and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Justine V. Cohen's work include Cancer Immunotherapy and Biomarkers (48 papers), Brain Metastases and Treatment (18 papers) and Melanoma and MAPK Pathways (18 papers). Justine V. Cohen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (48 papers), Brain Metastases and Treatment (18 papers) and Melanoma and MAPK Pathways (18 papers). Justine V. Cohen collaborates with scholars based in United States, Canada and France. Justine V. Cohen's co-authors include Ryan J. Sullivan, Donald P. Lawrence, Kerry L. Reynolds, Harriet M. Kluger, Alexander T. Faje, Tomas G. Neilan, Michael Constantin Kirchberger, John D. Groarke, Paaladinesh Thavendiranathan and Michael G. Fradley and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Justine V. Cohen

86 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

2018 1.1k citations Justine V. Cohen, Kerry L. Reynolds et al. profile →
High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma

2018 348 citations Donald P. Lawrence, Keith T. Flaherty et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Justine V. Cohen United States	22	2.4k	838	583	554	516	96	3.4k
Anne O’Neill United States	30	1.8k 0.8×	822 1.0×	620 1.1×	157 0.3×	505 1.0×	89	3.5k
Mary Louise Keohan United States	34	2.2k 0.9×	2.8k 3.3×	769 1.3×	627 1.1×	673 1.3×	105	4.4k
Sandra J. Strauss United Kingdom	30	1.3k 0.5×	1.5k 1.8×	223 0.4×	343 0.6×	844 1.6×	94	3.1k
Fariba Navid United States	31	896 0.4×	1.3k 1.6×	318 0.5×	303 0.5×	686 1.3×	104	2.8k
Annette Ramaswamy Germany	35	1.8k 0.7×	652 0.8×	358 0.6×	74 0.1×	1.2k 2.4×	110	3.7k
Peter Langmuir United States	30	1.8k 0.8×	1.6k 2.0×	888 1.5×	118 0.2×	1.3k 2.5×	56	4.7k
Stefan Knop Germany	33	2.1k 0.9×	273 0.3×	641 1.1×	240 0.4×	1.9k 3.8×	152	4.4k
Antonio López–Pousa Spain	32	1.7k 0.7×	1.9k 2.2×	175 0.3×	448 0.8×	541 1.0×	161	3.4k
Mohammad K. Khan United States	30	1.0k 0.4×	970 1.2×	373 0.6×	54 0.1×	432 0.8×	121	2.5k
Yusri Elsayed United States	22	1.1k 0.5×	606 0.7×	422 0.7×	196 0.4×	1.1k 2.0×	51	2.4k

Countries citing papers authored by Justine V. Cohen

Since Specialization

Citations

This map shows the geographic impact of Justine V. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justine V. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justine V. Cohen more than expected).

Fields of papers citing papers by Justine V. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justine V. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justine V. Cohen. The network helps show where Justine V. Cohen may publish in the future.

Co-authorship network of co-authors of Justine V. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Justine V. Cohen. A scholar is included among the top collaborators of Justine V. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justine V. Cohen. Justine V. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buchbinder, Elizabeth I., Justine V. Cohen, Giuseppe Tarantino, et al.. (2024). A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma. Cancer Research Communications. 4(5). 1321–1327. 7 indexed citations

Patel, Sapna P., Anastasios Dimou, Adrienne I. Victor, et al.. (2024). Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.. Journal of Clinical Oncology. 42(16_suppl). 9508–9508. 10 indexed citations

Abbott, James, Sarah Ahmed, Melissa Wilson, et al.. (2024). Inherited Basaloid Neoplasms Associated With SUFU Pathogenic Variants. JAMA Dermatology. 160(11). 1220–1220.

Rodon, Jordi, Marya Chaney, Justine V. Cohen, et al.. (2023). 627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. SHILAP Revista de lepidopterología. A716–A716.

Perets, Ruth, Salomon M. Stemmer, Ravit Geva, et al.. (2023). 161TiP A phase I/II, open-label study of an anti-ILT2 (LILRB1) antibody, SAR444881, administered alone and in combination with pembrolizumab, with or without chemotherapy, or cetuximab in patients with advanced solid tumors. Immuno-Oncology Technology. 20. 100672–100672. 1 indexed citations

Mooradian, Meghan J., James M. Cleary, Anita Giobbie‐Hurder, et al.. (2023). Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors. Cancer. 129(12). 1904–1918. 7 indexed citations

Miller, David M., Howard L. Kaufman, Kevin S. Emerick, et al.. (2022). Neoadjuvant Nivo/Rela for Resectable Melanoma. 1(1). 2 indexed citations

Anstadt, Emily J., Brian Chu, Nikhil Yegya‐Raman, et al.. (2022). Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. The Oncologist. 27(9). 799–808. 4 indexed citations

Etzkorn, Jeremy R., Jerry D. Brewer, Thuzar M. Shin, et al.. (2021). Systematic review and meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, Mohs micrographic surgery, or staged excision. Journal of the American Academy of Dermatology. 85(3). 681–692. 34 indexed citations

10.

Ham, Seokjin, Donald P. Lawrence, Justine V. Cohen, et al.. (2021). Rejection of benign melanocytic nevi by nevus-resident CD4 ⁺ T cells. Science Advances. 7(26). 9 indexed citations

11.

Bai, Xue, Michelle Kim, Gyulnara G. Kasumova, et al.. (2021). Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. Journal for ImmunoTherapy of Cancer. 9(2). e002092–e002092. 8 indexed citations

12.

Seethapathy, Harish, Donald F. Chute, Ian A. Strohbehn, et al.. (2020). Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. Kidney Medicine. 2(3). 373–375. 7 indexed citations

13.

Mooradian, Meghan J., James M. Cleary, Justine V. Cohen, et al.. (2020). CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3609–3609. 3 indexed citations

14.

Johnson, Douglas B., Justine V. Cohen, Alexandra M. Haugh, et al.. (2019). Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. Cancer Immunology Research. 7(11). 1755–1759. 20 indexed citations

15.

Dubey, Divyanshu, William David, Kerry L. Reynolds, et al.. (2019). Immune checkpoint inhibitor related neurologic adverse events: clinical spectrum, management and outcomes (S21.003). Neurology. 92(15_supplement). 2 indexed citations

16.

Badran, Yousef R., Justine V. Cohen, Priscilla K. Brastianos, et al.. (2019). Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. Journal for ImmunoTherapy of Cancer. 7(1). 226–226. 107 indexed citations

17.

Kluger, Harriet M., Christopher R. Zito, Gabriela Turcu, et al.. (2017). PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research. 23(15). 4270–4279. 111 indexed citations

18.

Cohen, Justine V. & Harriet M. Kluger. (2016). Systemic Immunotherapy for the Treatment of Brain Metastases. Frontiers in Oncology. 6. 49–49. 60 indexed citations

19.

Viola, Kate V., William G. Stebbins, Elizabeth C. Smith, et al.. (2015). Intralesional Bleomycin for Warts. Journal of Cutaneous Medicine and Surgery. 19(5). 470–476. 22 indexed citations

20.

Soung, Jennifer, Justine V. Cohen, Robert Phelps, & Steven R. Cohen. (2007). Case reports: minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy.. PubMed. 6(12). 1232–6. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact